251WW, Senior Director, Manufacturing Science and Technology (MSAT)

Job Code 251WW


Fate Therapeutics is seeking a highly motivated Senior Director, Manufacturing Science and Technology (MSAT), to provide technical and organizational leadership to develop solutions in support of clinical and commercial manufacturing for internal and external manufacturing operations. The position will provide program leadership for IND projects, liaison with Manufacturing, Process Science and Assay Development, Quality Assurance, Quality Control, Regulatory, Clinical and various project stakeholders to promote Product Development aims. The successful candidate will act as a Fate representative during interactions with US and international regulatory bodies and participate in CMC leadership team to set annual objectives. Fate’s development programs involve novel cell therapies which present with unique product manufacturing, quality and regulatory challenges. The ideal candidate should have experience in the area of cell therapy and/or biologics and be aware of the pertinent regulations and how they apply to these fields. This is a full-time position reporting to the SVP, Technical Operations and is located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 251WW.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.